Drug profile · INN
romiplostim
NPLATE
romiplostim (NPLATE) is a thrombopoietin receptor agonist. Associated with Amgen. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — romiplostim
- US status
- approved
- Class
- Blood and blood forming organs (B02)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
romiplostim (NPLATE) is a thrombopoietin receptor agonist. Associated with Amgen. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombopoietin receptor agonist
Primary target: Thrombopoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is romiplostim?
romiplostim (NPLATE) is a thrombopoietin receptor agonist. Associated with Amgen. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for romiplostim?
NPLATE is a marketed brand name for romiplostim. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of romiplostim?
romiplostim has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.